Premium
TLS‐CHOP target gene DOL54 expression in liposarcomas and malignant fibrous histiocytomas
Author(s) -
Domoto Hideharu,
Hosaka Taisuke,
Oikawa Kosuke,
Ohbayashi Tetsuya,
Ishida Tsuyoshi,
Izumi Miki,
Iwaya Keiichi,
Toguchida Junya,
Kuroda Masahiko,
Mukai Kiyoshi
Publication year - 2002
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1046/j.1440-1827.2002.01391.x
Subject(s) - liposarcoma , chop , cancer research , pathology , fusion gene , biology , oncogene , adipogenesis , chinese hamster ovary cell , sarcoma , gene , lymphoma , medicine , cell culture , mesenchymal stem cell , cell cycle , genetics , biochemistry
Downstream of the gene for the liposarcoma‐associated fusion oncoprotein 54 ( DOL54 ) is a target gene of the myxoid liposarcoma and round cell liposarcoma (M‐LPS/RC‐LPS) oncogene, TLS/FUS‐CHOP . The DOL54 gene product is closely associated with adipogenic differentiation. DOL54 overexpression resulted in tumorigenicity when Chinese Hamster Ovary (CHO) cells were injected subcutaneously into nude mice. The biological significance of DOL54 expression for human malignant soft tissue tumors, however, has not yet been investigated. We examined TLS‐CHOP and DOL54 expression in M‐LPS/RC‐LPS, well‐differentiated liposarcoma and malignant fibrous histiocytoma (MFH), a tumor whose cellular origin has not been determined. We observed DOL54 expression in 50% of M‐LPS/RC‐LPS cases (in which TLS‐CHOP was also expressed) and 33% of MFH cases, suggesting that a portion of MFH lesions may either derive from adipocytic precursor cells or have the potential to undergo adipogenic differentiation. In this manner, M‐LPS/RC‐LPS and MFH lesions may share tumorigenic characteristics, resulting from the unscheduled expression of DOL54.